Effects of depletion of EPAS1 and knocking down TNFSF10 in 786-O cell lines.

VHL loss leads to the stabilization of hypoxia-inducible factor a (HIFa), which may drive various tumor-promoting pathways. Here, we depletion expression of HIF2a in 786-O and performed transcriptome profiling to assess the molecular impact. TRAIL represents a promising avenue for cancer therapy due to its ability to selectively target and kill tumor cells. However, its effectiveness is variable across different cancer types, even with some tumors exhibiting high levels of TRAIL expression. To investigate this situation, we used shRNA to target TNFSF10, aiming to understand its impact on tumor development. Overall design: To analyze the differntial gene expression of 786-O kidney cancer cell lines under four different conditions to understand the effect of HIF2a knocking out via CRISPR-Cas9 and TNFSF10 knocking down using inducible shRNA (with and without doxycycline induction for 48 hours). Each condition will have its set of biological replicates to ensure statistical significance.